

# Jose R Arribas

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5941993/jose-r-arribas-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

210  
papers

9,221  
citations

52  
h-index

91  
g-index

242  
ext. papers

10,998  
ext. citations

6.9  
avg, IF

5.65  
L-index

#	Paper	IF	Citations
210	Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19 <b>2022</b> , 1,		18
209	Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection. <i>Aids</i> , <b>2022</b> , 36, 39-48	3.5	2
208	Melatonin in the Prophylaxis of SARS-CoV-2 Infection in Healthcare Workers (MeCOVID): A Randomised Clinical Trial.. <i>Journal of Clinical Medicine</i> , <b>2022</b> , 11,	5.1	2
207	Ageing with HIV: Challenges and biomarkers.. <i>EBioMedicine</i> , <b>2022</b> , 77, 103896	8.8	1
206	Acute hepatitis B among HIV positive persons: A two-decade review of cases from a Spanish cohort.. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)</i> , <b>2022</b> , 40, 121-124	0.1	
205	Efficacy of sotrovimab for persistent coronavirus disease-2019 in a severely immunocompromised person living with HIV.. <i>Aids</i> , <b>2022</b> , 36, 751-753	3.5	1
204	Impact of early interferon- $\beta$ treatment on the prognosis of patients with COVID-19 in the first wave: A post hoc analysis from a multicenter cohort.. <i>Biomedicine and Pharmacotherapy</i> , <b>2021</b> , 146, 112572	7.5	1
203	Prevention and Treatment of SARS-CoV2 Infection in People Living with HIV: The Need for Specific Data. <i>Infectious Diseases and Therapy</i> , <b>2021</b> , 1	6.2	1
202	Epigenetic age acceleration changes 2 years after antiretroviral therapy initiation in adults with HIV: a substudy of the NEAT001/ANRS143 randomised trial. <i>Lancet HIV,the</i> , <b>2021</b> , 8, e197-e205	7.8	14
201	Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy. <i>Annals of Internal Medicine</i> , <b>2021</b> , 174, 581-582	8	2
200	Impact of COVID-19 on Madrid hospital system. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)</i> , <b>2021</b> , 39, 256-257	0.1	16
199	Critical Care Requirements Under Uncontrolled Transmission of SARS-CoV-2. <i>American Journal of Public Health</i> , <b>2021</b> , 111, 923-926	5.1	2
198	Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort. <i>Clinical Microbiology and Infection</i> , <b>2021</b> , 27, 1678-1684	9.5	8
197	Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study. <i>Lancet Infectious Diseases, The</i> , <b>2021</b> , 21, 783-792	25.5	25
196	Longitudinal changes in epigenetic age acceleration in aviremic HIV-infected recipients of long-term antiretroviral treatment. <i>Journal of Infectious Diseases</i> , <b>2021</b> ,	7	3
195	Presenting characteristics and outcomes of migrants in a cohort of hospitalized patients with COVID-19: Does the origin matter?. <i>Travel Medicine and Infectious Disease</i> , <b>2021</b> , 42, 102027	8.4	3
194	Impact of COVID-19 on Madrid hospital system. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , <b>2021</b> , 39, 256-257	0.9	17

193	Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2021</b> , 76, 738-742	5.1	8
192	Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19). <i>Clinical Microbiology and Infection</i> , <b>2021</b> , 27, 244-252	9.5	61
191	Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score. <i>Thorax</i> , <b>2021</b> , 76, 920-929	7.3	12
190	Health Care Workers' Reasons for Choosing Between Two Different COVID-19 Prophylaxis Trials in an Acute Pandemic Context: Single-Center Questionnaire Study. <i>Journal of Medical Internet Research</i> , <b>2021</b> , 23, e23441	7.6	0
189	Risks and benefits of reducing the number of drugs to treat HIV-1 infection. <i>Expert Opinion on Drug Safety</i> , <b>2021</b> , 20, 397-409	4.1	2
188	Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. <i>Lancet, The</i> , <b>2021</b> , 398, 121-130	4.0	133
187	COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study. <i>HIV Medicine</i> , <b>2021</b> , 22, 867-876	2.7	2
186	Detection of archived lamivudine-associated resistance mutations in virologically suppressed, lamivudine-experienced HIV-infected adults by different genotyping techniques (GEN-PRO study). <i>Journal of Antimicrobial Chemotherapy</i> , <b>2021</b> , 76, 3263-3271	5.1	0
185	A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , <b>2020</b> , 21, 466	2.8	25
184	A Cohort of Patients with COVID-19 in a Major Teaching Hospital in Europe. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	146
183	Proof-of-concept trial of the combination of lactitol with and for the eradication of intestinal OXA-48-producing. <i>Gut Pathogens</i> , <b>2020</b> , 12, 15	5.4	4
182	Physicians' opinions on generic antiretroviral drugs and single-tablet regimen de-simplification for the treatment of HIV infection: a multicentre survey in Spain. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2020</b> , 75, 466-472	5.1	3
181	Comparison of Noninvasive Cardiac Test Strategies for Newly Diagnosed Chagas Disease in a Non-Endemic Zone. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>2020</b> , 103, 1480-1486	3.2	
180	Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2020</b> , 83, 310-318	3.1	52
179	Characteristics of Zika virus infection among international travelers: A prospective study from a Spanish referral unit. <i>Travel Medicine and Infectious Disease</i> , <b>2020</b> , 33, 101543	8.4	3
178	Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2020</b> , 75, 628-639	5.1	5
177	Antiretrovirals and Risk of COVID-19 Diagnosis and Hospitalization in HIV-Positive Persons. <i>Epidemiology</i> , <b>2020</b> , 31, e49-e51	3.1	11
176	Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO). <i>EBioMedicine</i> , <b>2020</b> , 55, 102779	8.8	14

175	Absence of IgG antibodies among high-risk contacts of two confirmed cases of Crimean-Congo haemorrhagic fever in the autonomous region of Madrid (Spain). <i>Journal of Infection and Public Health</i> , <b>2020</b> , 13, 1595-1598	7.4	1
174	Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy : A Cohort Study. <i>Annals of Internal Medicine</i> , <b>2020</b> , 173, 536-541	8	159
173	Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study. <i>AIDS Research and Therapy</i> , <b>2020</b> , 17, 45	3	
172	Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. <i>Lancet HIV,the</i> , <b>2020</b> , 7, e389-e400	7.8	27
171	Correlation between blood telomere length and CD4+ CD8+ T-cell subsets changes 96 weeks after initiation of antiretroviral therapy in HIV-1-positive individuals. <i>PLoS ONE</i> , <b>2020</b> , 15, e0230772	3.7	3
170	Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. <i>Aids</i> , <b>2019</b> , 33, 1455-1465	3.5	60
169	Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. <i>Lancet HIV,the</i> , <b>2019</b> , 6, e364-e372	7.8	55
168	Analysis of the costs and cost-effectiveness of the guidelines recommended by the 2018 GESIDA/Spanish National AIDS Plan for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , <b>2019</b> , 37, 151-159	0.1	1
167	New filovirus disease classification and nomenclature. <i>Nature Reviews Microbiology</i> , <b>2019</b> , 17, 261-263	22.2	38
166	Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial. <i>PLoS ONE</i> , <b>2019</b> , 14, e0209911	3.7	14
165	Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥ 50 Years: Final 96-Week Results of the NEAT022 Study. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 68, 597-606	11.6	18
164	Analysis of the costs and cost-effectiveness of the guidelines recommended by the 2018 GESIDA/Spanish National AIDS Plan for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , <b>2019</b> , 37, 151-159	0.9	4
163	Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 68, 1184-1192	11.6	7
162	Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. <i>Lancet, The</i> , <b>2018</b> , 392, 142-155	40	175
161	Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , <b>2019</b> , 37, 195-202	0.9	7
160	New Strategies of ARV: the Road to Simplification. <i>Current HIV/AIDS Reports</i> , <b>2018</b> , 15, 11-19	5.9	10
159	Doravirine versus ritonavir-boosted darunavir in antiretroviral-naïve adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. <i>Lancet HIV,the</i> , <b>2018</b> , 5, e211-e220	7.8	80
158	Therapeutic management of Crimean-Congo haemorrhagic fever. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , <b>2018</b> , 36, 517-522	0.9	2

157	Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , <b>2018</b> , 36, 268-276	0.9	5
156	Autochthonous Crimean-Congo haemorrhagic fever in Spain: So much to learn. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , <b>2018</b> , 36, 202	0.9	1
155	Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. <i>Lancet HIV</i> , <b>2018</b> , 5, e23-e34	7.8	64
154	Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2018</b> , 77, 102-109	3.1	2
153	Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1. <i>Journal of Infectious Diseases</i> , <b>2018</b> , 218, 1523-1530	7	13
152	Therapeutic management of Crimean-Congo haemorrhagic fever. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , <b>2018</b> , 36, 517-522	0.1	0
151	Autochthonous Crimean-Congo haemorrhagic fever in Spain: So much to learn. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , <b>2018</b> , 36, 202	0.1	
150	Impact of Nucleos(t)ide Reverse Transcriptase Inhibitors on Blood Telomere Length Changes in a Prospective Cohort of Aviremic HIV-Infected Adults. <i>Journal of Infectious Diseases</i> , <b>2018</b> , 218, 1531-1540 <sup>7</sup>		13
149	A safety evaluation of raltegravir for the treatment of HIV. <i>Expert Opinion on Drug Safety</i> , <b>2018</b> , 17, 217-223		6
148	Broad Neutralizing Activity Against Ebolaviruses Lacking the Mucin-Like Domain in Convalescent Plasma Specimens From Patients With Ebola Virus Disease. <i>Journal of Infectious Diseases</i> , <b>2018</b> , 218, S574-S581 <sup>5</sup>		
147	Short Communication: Maraviroc Once-Daily: Experience in Routine Clinical Practice. <i>AIDS Research and Human Retroviruses</i> , <b>2017</b> , 33, 29-32	1.6	5
146	Impact of Antiretroviral Treatment Containing Tenofovir Difumarate on the Telomere Length of Aviremic HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2017</b> , 76, 102-109 <sup>1</sup>		10
145	Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2017</b> , 75, 211-218	3.1	81
144	Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults. <i>Journal of Infectious Diseases</i> , <b>2017</b> , 215, 1789-1798	7	53
143	Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , <b>2017</b> , 35, 88-99	0.1	
142	Persistence and infectivity of Zika virus in semen after returning from endemic areas: Report of 5 cases. <i>Journal of Clinical Virology</i> , <b>2017</b> , 96, 110-115	14.5	27
141	Brief Report: Differential Effects of Tenofovir, Abacavir, Emtricitabine, and Darunavir on Telomerase Activity In Vitro. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2017</b> , 74, 91-94	3.1	5
140	Autochthonous Crimean-Congo Hemorrhagic Fever in Spain. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 154-161	59.2	101

139	Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , <b>2017</b> , 35, 88-99	0.9	6
138	Antiviral Therapy <b>2017</b> , 918-926.e1		
137	The Role of HIV-1 Drug-Resistant Minority Variants in Treatment Failure. <i>Journal of Infectious Diseases</i> , <b>2017</b> , 216, S847-S850	7	26
136	Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Controlled Trial. <i>Journal of Infectious Diseases</i> , <b>2017</b> , 215, S101-S107	11.6	71
135	Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI. <i>HIV Clinical Trials</i> , <b>2017</b> , 18, 118-125		11
134	P045 Switching from boosted atazanavir (ATV) plus FTC/TDF to a TAF-based single tablet regimen (STR): week 48 data in virologically suppressed adults. <i>Sexually Transmitted Infections</i> , <b>2016</b> , 92, A34.1-A34.8		28
133	Long-Term Control of Human Immunodeficiency Virus-1 Replication Despite Extensive Resistance to Current Antiretroviral Regimens: Clonal Analysis of Resistance Mutations in Proviral Deoxyribonucleic Acid. <i>Open Forum Infectious Diseases</i> , <b>2016</b> , 3, ofw041	1	1
132	Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2016</b> , 71, 530-7	3.1	132
131	Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naïve adults: week 96 efficacy and safety from a randomized phase 3b study. <i>Aids</i> , <b>2016</b> , 30, 251-9	3.5	29
130	Switching from tenofovir containing regimens to boosted protease inhibitor monotherapy: Impact on renal function. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , <b>2016</b> , 34, 29-32	0.9	
129	Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , <b>2016</b> , 34, 516.e1-516.e18	0.9	6
128	Clinical Management of Ebola Virus Disease in the United States and Europe. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 636-46	59.2	246
127	Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus. <i>Virus Research</i> , <b>2016</b> , 213, 224-229	6.4	22
126	Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , <b>2016</b> , 34, 361-71	0.9	10
125	Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. <i>Lancet Infectious Diseases</i> , <b>2016</b> , 16, 43-52	25.5	211
124	Topical cidofovir to treat high-grade anal intraepithelial neoplasia in HIV-infected patients: a pilot clinical trial. <i>Aids</i> , <b>2016</b> , 30, 75-82	3.5	10
123	Efficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials. <i>HIV Medicine</i> , <b>2016</b> , 17, 358-67	2.7	53
122	Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2016</b> , 72, 58-64	3.1	89

121	Community-Onset Bloodstream and Other Infections, Caused by Carbapenemase-Producing : Epidemiological, Microbiological, and Clinical Features. <i>Open Forum Infectious Diseases</i> , <b>2016</b> , 3, ofw136 <sup>1</sup>	13
120	Probable sexual transmission of Zika virus from a vasectomised man. <i>Lancet Infectious Diseases, The</i> , <b>2016</b> , 16, 1107	25.5 110
119	Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease contracted in Madrid, Spain. <i>Lancet Respiratory Medicine, the</i> , <b>2015</b> , 3, 554-62	35.1 100
118	Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. <i>Lancet Infectious Diseases, The</i> , <b>2015</b> , 15, 705-08	25.5 111
117	Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial. <i>Lancet HIV, the</i> , <b>2015</b> , 2, e464-73	7.8 60
116	Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF. <i>Patient</i> , <b>2015</b> , 6, 145-54	3.7 10
115	Treatment of Ebola virus disease. <i>Intensive Care Medicine</i> , <b>2015</b> , 41, 115-7	14.5 21
114	Week 48 efficacy and central nervous system analysis of darunavir/ritonavir monotherapy versus darunavir/ritonavir with two nucleoside analogues. <i>Aids</i> , <b>2015</b> , 29, 1811-20	3.5 27
113	Second-line antiretroviral therapy and the human factor. <i>Lancet HIV, the</i> , <b>2015</b> , 2, e34-5	7.8
112	Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials. <i>Clinical Infectious Diseases</i> , <b>2014</b> , 59, 425-34	11.6 39
111	Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. <i>Lancet, The</i> , <b>2014</b> , 384, 1942-51	40 136
110	Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , <b>2014</b> , 32, 447-58	0.9 10
109	Inflammatory, procoagulant markers and HIV residual viremia in patients receiving protease inhibitor monotherapy or triple drug therapy: a cross-sectional study. <i>BMC Infectious Diseases</i> , <b>2014</b> , 14, 379	4 9
108	Pattern of neurocognitive function in patients receiving boosted protease inhibitor monotherapy: a detailed neuropsychological study. <i>Journal of NeuroVirology</i> , <b>2014</b> , 20, 362-70	3.9 6
107	Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. <i>Lancet Infectious Diseases, The</i> , <b>2014</b> , 14, 572-80	25.5 120
106	Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. <i>Neurology</i> , <b>2014</b> , 83, 134-41	6.5 85
105	Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial. <i>Lancet Infectious Diseases, The</i> , <b>2014</b> , 14, 581-9	25.5 95
104	FLAMINGO: how much rosier can antiretroviral therapy get?. <i>Lancet, The</i> , <b>2014</b> , 383, 2191-3	40 4

103	Simplification to Stribild vs continuation of RTV-boosted DRV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-PI subgroup analysis. <i>Journal of the International AIDS Society</i> , <b>2014</b> , 17, 19805	5.4	3
102	Long-term control of HIV replication with dolutegravir and pegylated interferon alpha-2a in an HIV-infected patient with sextuple-class resistance. <i>Aids</i> , <b>2014</b> , 28, 932-4	3.5	2
101	No difference in the rate of change in telomere length or telomerase activity in HIV-infected patients after three years of darunavir/ritonavir with and without nucleoside analogues in the MONET trial. <i>PLoS ONE</i> , <b>2014</b> , 9, e109718	3.7	11
100	Changes in lipid levels after 48 weeks of dual versus triple therapy observed in the GARDEL study. <i>Journal of the International AIDS Society</i> , <b>2014</b> , 17, 19554	5.4	2
99	The PROTEA trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV-1 RNA below 50 copies/mL. <i>Journal of the International AIDS Society</i> , <b>2014</b> , 17, 19525	5.4	16
98	Renal safety profile of STB in virologically suppressed subjects from two randomized phase 3b switch trials. <i>Journal of the International AIDS Society</i> , <b>2014</b> , 17, 19807	5.4	
97	Facial emotional processing deficits in long-term HIV-suppressed patients. <i>Journal of the International AIDS Society</i> , <b>2014</b> , 17, 19664	5.4	2
96	Cerebral volumes, neuronal integrity and brain inflammation measured by MRI in patients receiving PI monotherapy or triple therapy. <i>Journal of the International AIDS Society</i> , <b>2014</b> , 17, 19578	5.4	7
95	Cost/efficacy analysis of preferred Spanish AIDS study group regimens and the dual therapy with LPV/r+3TC for initial ART in HIV infected adults. <i>Journal of the International AIDS Society</i> , <b>2014</b> , 17, 19603	5.4	
94	Efficacy of PI monotherapy versus triple therapy for 1964 patients in 10 randomised trials. <i>Journal of the International AIDS Society</i> , <b>2014</b> , 17, 19788	5.4	16
93	Incidence of hepatocellular carcinoma in HIV-infected patients with cirrhosis: a prospective study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2014</b> , 65, 82-6	3.1	10
92	Assessment of second-line antiretroviral regimens for HIV therapy in Africa. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 234-47	59.2	147
91	A prospective cohort study of neurocognitive function in aviremic HIV-infected patients treated with 1 or 3 antiretrovirals. <i>Clinical Infectious Diseases</i> , <b>2014</b> , 59, 1627-34	11.6	17
90	Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults. <i>Aids</i> , <b>2014</b> , 28, 989-97	3.5	90
89	A comparative study of neurocognitively impaired patients receiving protease inhibitor monotherapy or triple-drug antiretroviral therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2014</b> , 67, 419-23	3.1	4
88	Boosted protease inhibitor monotherapy in HIV-infected adults: outputs from a pan-European expert panel meeting. <i>AIDS Research and Therapy</i> , <b>2013</b> , 10, 3	3	20
87	Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons. <i>Clinical Infectious Diseases</i> , <b>2013</b> , 57, 112-21	11.6	45
86	A benchmark for management of drug resistant HIV. <i>Lancet Infectious Diseases</i> , <b>2013</b> , 13, 561-2	25.5	



85	Dynamics of cellular HIV-1 DNA levels over 144 weeks of darunavir/ritonavir monotherapy versus triple therapy in the MONET trial. <i>HIV Clinical Trials</i> , <b>2013</b> , 14, 45-50		23
84	Is etravirine and two nucleosides an option for HIV with an isolated K103N mutation?. <i>Aids</i> , <b>2013</b> , 27, 141-4	3.5	2
83	Advances in antiretroviral therapy. <i>Current Opinion in HIV and AIDS</i> , <b>2013</b> , 8, 341-9	4.2	28
82	Predictors of long-term HIV RNA suppression on darunavir/ritonavir monotherapy in the MONET trial. <i>International Journal of STD and AIDS</i> , <b>2013</b> , 24, 679-81	1.4	9
81	96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study. <i>Antiviral Therapy</i> , <b>2013</b> , 18, 905-13	1.6	52
80	Neurocognitive impairment in patients treated with protease inhibitor monotherapy or triple drug antiretroviral therapy. <i>PLoS ONE</i> , <b>2013</b> , 8, e69493	3.7	19
79	Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. <i>Lancet Infectious Diseases</i> , <b>2012</b> , 12, 111-8	25.5	212
78	Updating Our Understanding of Pulmonary Disease Associated With HIV Infection. <i>Archivos De Bronconeumologia</i> , <b>2012</b> , 48, 126-132	0.7	3
77	No evidence for evolution of protease inhibitor resistance from standard genotyping, after three years of treatment with darunavir/ritonavir, with or without nucleoside analogues. <i>AIDS Research and Human Retroviruses</i> , <b>2012</b> , 28, 1167-9	1.6	9
76	Detection and quantification of the K103N mutation in HIV reverse transcriptase by pyrosequencing. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2012</b> , 72, 90-6	2.9	7
75	Imported Plasmodium falciparum malaria in HIV-infected patients: a report of two cases. <i>Malaria Journal</i> , <b>2012</b> , 11, 136	3.6	3
74	Protease inhibitor monotherapy: what is its role?. <i>Current HIV/AIDS Reports</i> , <b>2012</b> , 9, 179-85	5.9	6
73	Updating our understanding of pulmonary disease associated with HIV infection. <i>Archivos De Bronconeumologia</i> , <b>2012</b> , 48, 126-32	0.7	3
72	Interleukin-6 and C-reactive protein levels after 3 years of treatment with darunavir/ritonavir monotherapy or darunavir/ritonavir + two nucleoside reverse transcriptase inhibitors in the MONET trial. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2012</b> , 67, 1804-6	5.1	5
71	Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. <i>Lancet Infectious Diseases</i> , <b>2011</b> , 11, 907-15	25.5	155
70	Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis. <i>PLoS ONE</i> , <b>2011</b> , 6, e22003	3.7	83
69	Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy. <i>Antiviral Therapy</i> , <b>2011</b> , 16, 59-65	1.6	16
68	Hypertension and isolated office hypertension in HIV-infected patients determined by ambulatory blood pressure monitoring: prevalence and risk factors. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2011</b> , 58, 54-9	3.1	27

67	Protease inhibitor monotherapy. <i>Current Opinion in Infectious Diseases</i> , <b>2011</b> , 24, 7-11	5.4	29
66	The natural history of liver cirrhosis in HIV-hepatitis C virus-coinfected patients. <i>Aids</i> , <b>2011</b> , 25, 899-904	3.5	56
65	Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy. <i>Aids</i> , <b>2011</b> , 25, 1683-90	3.5	34
64	Inappropriate claim of 'failure of ritonavir-boosted lopinavir monotherapy in HIV' in the Monotherapy Switzerland/Thailand (MOST) trial. <i>Aids</i> , <b>2011</b> , 25, 393-4	3.5	7
63	Single genome sequencing of HIV-1 gag and protease resistance mutations at virologic failure during the OK04 trial of simplified versus standard maintenance therapy. <i>Antiviral Therapy</i> , <b>2011</b> , 16, 725-32	1.6	16
62	Estudio farmacoeconómico de lopinavir/ritonavir en monoterapia en el ensayo clínico OK04. <i>Pharmacoeconomics - Spanish Research Articles</i> , <b>2011</b> , 8, 85-98		1
61	Improvement in vitamin D deficiency following antiretroviral regime change: Results from the MONET trial. <i>AIDS Research and Human Retroviruses</i> , <b>2011</b> , 27, 29-34	1.6	76
60	Protease inhibitor monotherapy and the CNS: peace of mind?. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2011</b> , 66, 1954-62	5.1	40
59	96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2011</b> , 66, 1878-85	5.1	50
58	Restoration of T cell responses to toxoplasma gondii after successful combined antiretroviral therapy in patients with AIDS with previous toxoplasmic encephalitis. <i>Clinical Infectious Diseases</i> , <b>2011</b> , 52, 662-70	11.6	17
57	Neuropatogénesis inducida por el virus del sida: estrategias terapéuticas frente a la neurodegeneración inducida por la glucoproteína gp120/Tat en el sistema nervioso central. <i>Revista De Neurologia</i> , <b>2011</b> , 52, 101	24	4
56	Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. <i>Clinical Infectious Diseases</i> , <b>2010</b> , 51, 963-72	11.6	327
55	The future of antiretroviral therapy: challenges and needs. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2010</b> , 65, 827-35	5.1	39
54	Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trial. <i>AIDS Research and Human Retroviruses</i> , <b>2010</b> , 26, 747-57	1.6	15
53	Influenza A pandemic (H1N1) 2009 virus and HIV. <i>Emerging Infectious Diseases</i> , <b>2010</b> , 16, 1175-6	10.2	7
52	Treatment of visceral leishmaniasis with intravenous pentamidine and oral fluconazole in an HIV-positive patient with chronic renal failure--a case report and brief review of the literature. <i>International Journal of Infectious Diseases</i> , <b>2010</b> , 14, e522-5	10.5	32
51	Neuropsychiatric adverse events with ritonavir-boosted darunavir monotherapy in HIV-infected individuals: a randomised prospective study. <i>HIV Clinical Trials</i> , <b>2010</b> , 11, 163-9		25
50	Incorrect attribution of cerebrospinal fluid HIV-1 virological escape and lymphocytic meningitis to lopinavir/ritonavir monotherapy. <i>Aids</i> , <b>2010</b> , 24, 2415-6	3.5	

49	Response to: Assessment of Baseline HIV Viral Load as a Risk Factor for Loss of Virologic Suppression in Protease Inhibitor-Based Monotherapy Trials <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2010</b> , 53, 670	3.1	
48	The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. <i>Aids</i> , <b>2010</b> , 24, 223-30	3.5	148
47	Smoking-related health risks among persons with HIV in the Strategies for Management of Antiretroviral Therapy clinical trial. <i>American Journal of Public Health</i> , <b>2010</b> , 100, 1896-903	5.1	202
46	Neurocognitive disorders during antiretroviral treatment, despite full HIV RNA suppression. <i>HIV Therapy</i> , <b>2010</b> , 4, 257-260		3
45	Causes and consequences of incomplete HIV RNA suppression in clinical trials. <i>HIV Clinical Trials</i> , <b>2009</b> , 10, 289-98		23
44	Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2009</b> , 51, 1473-52	3.1	96
43	HAART is associated with lower hepatic necroinflammatory activity in HIV-hepatitis C virus-coinfected patients with CD4 cell count of more than 350 cells/microl at the time of liver biopsy. <i>Aids</i> , <b>2009</b> , 23, 971-5	3.5	25
42	Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine). <i>Current Opinion in HIV and AIDS</i> , <b>2009</b> , 4, 507-12	4.2	11
41	A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2009</b> , 51, 290-7	3.1	62
40	Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression. <i>Antiviral Therapy</i> , <b>2009</b> , 14, 195-201	1.6	11
39	Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression. <i>Antiviral Therapy</i> , <b>2009</b> , 14, 195-201	1.6	38
38	<i>Pneumocystis jirovecii</i> pneumonia in Spanish HIV-infected patients in the combined antiretroviral therapy era: prevalence of dihydropteroate synthase mutations and prognostic factors of mortality. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2008</b> , 62, 34-43	2.9	40
37	Long-term (4 years) efficacy of lopinavir/ritonavir monotherapy for maintenance of HIV suppression. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2008</b> , 61, 1359-61	5.1	45
36	Noninferiority and lopinavir/ritonavir monotherapy trials. <i>Aids</i> , <b>2008</b> , 22, 1696-7	3.5	4
35	Lipid and apoprotein profile in HIV-1-infected patients after CD4-guided treatment interruption. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2008</b> , 48, 455-9	3.1	9
34	Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naïve patients: 144-week analysis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2008</b> , 47, 74-8	3.1	184
33	A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. <i>Journal of Infectious Diseases</i> , <b>2008</b> , 198, 234-40	7	83
32	Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. <i>Aids</i> , <b>2008</b> , 22, F1-9	3.5	109

31	Immunological predictors of CD4+ T cell decline in antiretroviral treatment interruptions. <i>BMC Infectious Diseases</i> , <b>2008</b> , 8, 20	4	1
30	Obstetric and perinatal complications in HIV-infected women. Analysis of a cohort of 167 pregnancies between 1997 and 2003. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , <b>2007</b> , 86, 409-15	3.8	37
29	Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2007</b> , 46, 118; author reply 118-9	3.1	4
28	The level of persistent HIV viremia does not increase after successful simplification of maintenance therapy to lopinavir/ritonavir alone. <i>Aids</i> , <b>2006</b> , 20, 2331-5	3.5	16
27	Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. <i>New England Journal of Medicine</i> , <b>2006</b> , 354, 251-60	59.2	742
26	Pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus-coinfected subjects with hepatic impairment. <i>Journal of Clinical Pharmacology</i> , <b>2006</b> , 46, 265-74	2.9	28
25	Discontinuation of primary and secondary <i>Toxoplasma gondii</i> prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial. <i>Clinical Infectious Diseases</i> , <b>2006</b> , 43, 79-89	11.6	36
24	Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations. <i>HIV Clinical Trials</i> , <b>2006</b> , 7, 86-96		21
23	Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naïve patients: virologic, immunologic, and morphologic changes--a 96-week analysis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2006</b> , 43, 535-40	3.1	199
22	Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2005</b> , 40, 280-7	3.1	139
21	Nuevas dianas y nuevos fármacos en el tratamiento de la infección por el VIH. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , <b>2005</b> , 23, 25-32	0.9	
20	Lipid disorders in antiretroviral-naïve patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2005</b> , 55, 800-4	5.1	69
19	The rise and fall of triple nucleoside reverse transcriptase inhibitor (NRTI) regimens. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2004</b> , 54, 587-92	5.1	9
18	Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2004</b> , 53, 540-3	5.1	70
17	Prevention of opportunistic infections in adult and adolescent patients with HIV infection. GESIDA/National AIDS Plan guidelines, 2004 [correction]. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , <b>2004</b> , 22, 160-76	0.9	2
16	Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients with advanced HIV infection (EfaVIP 2 study). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2004</b> , 35, 343-50	3.1	42
15	Prevención de las infecciones oportunistas en pacientes adultos y adolescentes infectados por el VIH. Recomendaciones de GESIDA/Plan Nacional sobre el Sida. Año 2003. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , <b>2004</b> , 22, 160-176	0.9	3
14	Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. <i>Aids</i> , <b>2003</b> , 17, 1023-8	3.5	143

13	Treatment of advanced HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2003</b> , 51, 225-7	5.1	1
12	Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. <i>Clinical Infectious Diseases</i> , <b>2002</b> , 34, 838-46	11.6	152
11	Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. <i>New England Journal of Medicine</i> , <b>2002</b> , 346, 2039-46	59.2	561
10	High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/microl and opportunistic diseases: the EfaVIP Study (Efavirenz in Very Immunosuppressed Patients). <i>Aids</i> , <b>2002</b> , 16, 1554-6	3.5	18
9	Epidemiological trends of HIV infection in Spain. <i>Aids</i> , <b>2002</b> , 16, 2496-2499	3.5	13
8	Drug resistance in patients experiencing early virological failure under a triple combination including indinavir. <i>Aids</i> , <b>2001</b> , 15, 1701-6	3.5	49
7	Comparison of NNRTIs in antiretroviral-naïve patients. <i>International Journal of STD and AIDS</i> , <b>2001</b> , 12 Suppl 4, 3-9	1.4	2
6	Impact of protease inhibitor therapy on HIV-related oropharyngeal candidiasis. <i>Aids</i> , <b>2000</b> , 14, 979-85	3.5	67
5	Parvovirus B19-related anemia in an HIV-infected patient: rapid control after production of neutralizing antibodies during highly active antiretroviral therapy. <i>Annals of Internal Medicine</i> , <b>2000</b> , 132, 1011	8	10
4	Interferon plus ribavirin in HIV-infected patients with chronic hepatitis C. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>1999</b> , 22, 308-9	3.1	14
3	Cytomegalovirus encephalitis. <i>Annals of Internal Medicine</i> , <b>1996</b> , 125, 577-87	8	153
2	Magnetic resonance brain imaging lacks sensitivity for AIDS associated cytomegalovirus encephalitis. <i>Journal of NeuroVirology</i> , <b>1996</b> , 2, 397-403	3.9	27
1	A new murine model of severe acute toxoplasma encephalitis. <i>Journal of Antimicrobial Chemotherapy</i> , <b>1995</b> , 36, 503-12	5.1	4